|
Bivalent
|
Quadrivalent
|
Nonavalent
|
|||||
|---|---|---|---|---|---|---|---|
|
Cecolin
|
Cervarix
|
Walrinvax
|
Gardasil
|
CERVAVAC
|
Tsegardex
|
Gardasil 9
|
Cecolin 9
|
|
Xiamen Innovax Biotech
|
GlaxoSmithKline Biologicals
|
Walvax Biotechnonology
|
Merck Vaccines/MSD
|
Serum institute of India
|
Nanolel
|
Merck Vaccines/MSD
|
Xiamen Innovax Biotech
|
|
China
|
EMA
|
China
|
FDA
|
India
|
Russian Federation
|
FDA
|
China
|
|
12/30/2019
|
09/20/2007
|
2022-03-22
|
2006-06-08
|
2022-07-12
|
2025-03-05
|
2014-12-10
|
2025-05-30
|
|
NA
|
10/16/2009
|
N/A
|
2006-06-08
|
N/A
|
N/A
|
2014-12-10
|
N/A
|
|
NA
|
09/20/2007
|
N/A
|
2006-09-20
|
N/A
|
N/A
|
2015-06-10
|
N/A
|
|
10/14/2021
|
07/08/2009
|
2024-08-02
|
2009-05-20
|
N/A
|
N/A
|
2018-02-09
|
N/A
|
|
HPV type 16 L1 protein - 40 μg, |
HPV type 16 L1 protein - 20 μg, |
0 |
HPV Type 6 L1 protein - 20 μg |
0 |
HPV Type 6 L1 protein |
HPV Type 6 L1 protein - 20 μg |
0 |
|
Eschericia Coli
|
Baculovirus
|
Pichia Pastoris
|
Yeast (Saccharomyces cerevisiae)
|
Hansenula polymorpha
|
Yeast (Saccharomyces cerevisiae)
|
Yeast (Saccharomyces cerevisiae)
|
Eschericia Coli
|
|
Aluminium hydroxide |
AS04 (Aluminium hydroxide and 3-deacylated monophosphoryl lipid A) |
Aluminium phosphate |
Aluminium hydroxiphophate Sulphate |
Aluminium hydroxide |
Yes (not known) |
Aluminium hydroxiphophate Sulphate |
Aluminium hydroxide |
|
None |
None |
None |
None |
None |
None |
None |
None |
|
Not required
|
Not required
|
Not required
|
Not required
|
Not required
|
Not required
|
Not required
|
Not required
|
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
Liquid Ready to use
|
|
1-dose glass (Type 1) vial (0.5ml) |
1 or 2 dose glass (type 1) vial (0.5ml/dose) |
1-dose vial (0.5ml) |
1 dose vial (0.5ml/dose) |
1 / 2 dose glass (type 1) vial (0.5ml/dose) |
1 dose vial (0.5ml/dose) |
0 |
1-dose glass (Type 1) vial (0.5ml) |
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
Intramuscolar
|
|
36 months
|
60 months
|
36 months
|
36 months
|
24 months
|
0
|
36 months
|
36 months
|
|
2-8C
|
2-8C
|
2-8C
|
2-8C
|
2-8C
|
2-8C
|
2-8C
|
2-8C
|
|
Type 14
|
Type 30
|
Type 14
|
Type 30
|
Type 30
|
Not known
|
None
|
Type 14
|
|
14.29 (carton 10 vials) |
One dose vial: 57.7cm3/dose (carton 1 vial) - 11.5 (carton 10 vials) - 9.7 (carton 100 vials) |
11.8 cm3 (carton 20 vials) |
74.7 (carton 1 vial) |
N/A
|
N/A
|
18.4 (carton 10 vials UNICEF) |
(carton 10 vials) |
|
Female from 9 to 14 years of age: Two doses of 0.5 mL or three doses of 0.5mL. |
Age 9 to and including 14 years - Two doses each of 0.5 ml. |
Female from 9 to 14 years of age: Two doses of 0.5 mL or three doses of 0.5mL. |
Age 9 to and including 13 years - Two doses each of 0.5 ml. |
Age from 9 to 14 years: Two doses of 0.5 mL |
Age 18 to 45: Three doses of 0.5ml |
Age 9 to and including 14 years - Two doses each of 0.5 ml. |
Female from 9 to 17 years of age: Two doses of 0.5 mL or three doses of 0.5mL. |
|
Not required |
There are no safety, immunogenicity or efficacy data to support interchangeability of Cervarix with |
N/A
|
There are no safety, immunogenicity or efficacy data to support change during vaccination with |
It is recommended that individuals who receive a first dose of CERVAVAC® complete the vaccination course with CERVAVAC |
N/A
|
Studies using a mixed regimen (interchangeability) of HPV vaccines were not performed for Gardasil 9. |
N/A
|
|
N/A
|
Not required |
Not required |
Not required |
Not required |
Not required |
Not required |
Not required |
|
N/A
|
Cervarix is not recommended for use in children below 9 years of age due to limited data on safety |
N/A
|
The safety and efficacy of Gardasil in children below 9 years of age have not been established. No data are available. |
The safety and efficacy of CERVAVAC® in children below 9 years of age have not been established. No data are available. |
N/A
|
The safety and efficacy of Gardasil9 in children below 9 years of age have not been established. No data are available |
N/A
|
|
YES
|
YES
|
YES
|
YES
|
NO
|
NO
|
YES
|
NO
|
|
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
Detailed pricing information for UNICEF and PAHO procurement can be found at: https://www.unicef.org/supply/documents/human-papilloma-virus-hpv-vacci… and https://www.paho.org/en/documents/revolving-fund-vaccine-prices-2025 |
|
1. World Health Organization (2023). Prequalified vaccines [online database]. Geneva: WHO (https://extranet.who.int/prequal/vaccines/prequalified-vaccines, accessed 19 June 2025). |
1. European Medicines Agency (n.d.). Cervarix: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/cervarix-epa…, accessed 19 June 2025). |
1. World Health Organization (2023). Prequalified vaccines [online database]. Geneva: WHO (https://extranet.who.int/prequal/vaccines/prequalified-vaccines, accessed 19 June 2025). |
1. European Medicines Agency (n.d.). Gardasil: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/gardasil-epa…, accessed 19 June 2025). |
1. Serum Institute of India (2025). Cervavac [website]. Pune: Serum Institute of India (https://www.seruminstitute.com/product_ind_cervavac.php, accessed 19 June 2025). |
1. Nanolek website (2025) https://nanolek.ru/en/news/companynews/nanolek-received-a-registration-… (accessed on 1 July 2025) |
1. European Medicines Agency (n.d.). Gardasil 9: EU summary of product characteristics [product information document]. Amsterdam: EMA (https://www.ema.europa.eu/en/documents/product-information/gardasil-9-e…, accessed 19 June 2025). |
1. Xinhua News Agency (2025). China approves new domestically developed HPV vaccine. [website]. (https://english.news.cn/20250530/3c129f096e0842b2a2d4e43f82a190ca/c.html, accessed 19 June 2025). |
Vaccine Evidence Compendium
HPV vaccines
